Have a Quest rep contact me.

The role of particle size and density in cardiovascular risk

Learn more about emerging biomarkers that can help you identify residual risk

Size and Density Matter: How Advanced Lipid Testing Can Uncover Residual Risk

Despite a continued focus on traditional markers to manage cardiovascular risk, assessment has evolved beyond lipid values. Studies have shown that assessing low-density lipoprotein (LDL) particle number, size, and density can help identify residual risk among patients already being monitored or treated with statin therapy.

Download our white paper to:

  • Review the role of particle size and density in cardiovascular disease risk
  • Learn about the lipoprotein biomarkers that can help you accurately assess risk among patients already being monitored or treated
  • Find out how advanced lipid testing can help you take action against residual risk

Looking beyond traditional risk factors can help you improve your management of cardiovascular patients. Find out how in “Size and Density Matter: How Advanced Lipid Testing Can Uncover Residual Risk.”

Learn more about lipoprotein biomarkers—and how they can help uncover residual risk.

Complete the form and click submit.
*Indicates required fields

This website uses cookies for improvement of quality and user experience. By continuing to use the site, you confirm your awareness and acceptance of our use of cookies. For more information or to opt out of the use of cookies, see our Cookies Notice.